Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bishop

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
The Journal of Biological Chemistry|July 12, 2005
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activityAndrea D Basso, Asra Mirza, Gongjie Liu, et al.
Cureus|November 17, 2025
Implementation of a Novel, Intensive, Two-Week Simulation Rotation for Pediatric Residents to Teach Crisis Resource Management SkillsLorel R Huber, Robert Bishop, Shannon M Flood, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2004
Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced bindingF George Njoroge, Bancha Vibulbhan, Patrick Pinto, et al.
Experimental Cell Research|February 2, 2002
Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-RasDiana L Brassard, Jessie M English, Michael Malkowski, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Enhanced FTase activity achieved via piperazine interaction with catalytic zincF George Njoroge, Bancha Vibulbhan, Patrick Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2004
Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stabilityF George Njoroge, Bancha Vibulbhan, Xiongwei Shi, et al.
Advances in Anesthesia|January 22, 2024
Reconceptualizing Acute Pain Management in the 21st CenturyStephen Macres, Robin J Aldwinckle, Usha Saldahna, et al.
International Journal of Cancer|June 17, 2009
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer modelsGongjie Liu, Stacey A Taylor, Cindy H Marrinan, et al.
Bioorganic & Medicinal Chemistry|December 7, 2002
Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferaseF George Njoroge, Bancha Vibulbhan, Patrick Pinto, et al.
Gynecologic Oncology|February 2, 2008
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivoStacey A Taylor, Cindy H Marrinan, Gongjie Liu, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|July 12, 2005
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activityAndrea D Basso, Asra Mirza, Gongjie Liu, et al.
Cureus|November 17, 2025
Implementation of a Novel, Intensive, Two-Week Simulation Rotation for Pediatric Residents to Teach Crisis Resource Management SkillsLorel R Huber, Robert Bishop, Shannon M Flood, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2004
Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced bindingF George Njoroge, Bancha Vibulbhan, Patrick Pinto, et al.
Experimental Cell Research|February 2, 2002
Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-RasDiana L Brassard, Jessie M English, Michael Malkowski, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Enhanced FTase activity achieved via piperazine interaction with catalytic zincF George Njoroge, Bancha Vibulbhan, Patrick Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2004
Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stabilityF George Njoroge, Bancha Vibulbhan, Xiongwei Shi, et al.
Advances in Anesthesia|January 22, 2024
Reconceptualizing Acute Pain Management in the 21st CenturyStephen Macres, Robin J Aldwinckle, Usha Saldahna, et al.
International Journal of Cancer|June 17, 2009
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer modelsGongjie Liu, Stacey A Taylor, Cindy H Marrinan, et al.
Bioorganic & Medicinal Chemistry|December 7, 2002
Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferaseF George Njoroge, Bancha Vibulbhan, Patrick Pinto, et al.
Gynecologic Oncology|February 2, 2008
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivoStacey A Taylor, Cindy H Marrinan, Gongjie Liu, et al.
Pageof 6